Effect of β-receptor Blocker before PCI Perfusion in Patients with Acute Myocardial Infarction

CAO Qing

doi:10.14033/j.cnki.cfmr.2025.10.008

Abstract：Objective:To analyze the effect of β-receptor blocker before percutaneous coronary intervention(PCI)in patients with acute myocardial infarction(AMI).Method:A total of 101 patients with AMI admitted to the Jiangsu Province(Suqian)Hospital from April 2022 to April 2024 were selected and divided into control group(n=50)and observation group(n=51)according to different treatment methods.Both teams underwent standard PCI treatment protocol,with the observation group receiving β-receptor blocker(Esolol Hydrochloride)treatment before PCI infusion,and the control team receiving Physiological Saline as a placebo.The levels of cardiac damage markers and cardiac function between two groups of patients before and after surgery,and calculate the incidence of major cardiovascular adverse events(MACE)and cardiac rupture in both groups of patients were compared.Result:At 1 week after surgery,the levels of creatine kinase isoenzyme(CK-MB),cardiac troponin I(cTnI)and n-terminal natriuretic peptide precursor(NT-proBNP)in observation group were significantly lower than those in control group,the differences were statistically significant(P<0.05).At 1 week after surgery,left ventricular ejection fraction(LVEF)and left ventricular short axis shortening rate(LVFS)in observation group were higher than those in control group,the differences were statistically significant(P<0.05).Within 6 months after surgery,the incidence of MACE in observation group was lower than that in control group,the difference was statistically significant(P<0.05).There was no cardiac rupture in the observation group and 1 case in the control group,and there was no statistical significance between the two groups(P>0.05).Conclusion:The use of β-receptor blocker before PCI in patients with AMI can improve the cardiac function,reduce the level of myocardial injury markers and the occurrence of MACE.